Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infectious Diseases and Therapy
Published in: Infectious Diseases and Therapy 2/2015

Open Access 01-06-2015 | Review

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications

Authors: Kirpal Kaur, Mona A. Gandhi, Judianne Slish

Published in: Infectious Diseases and Therapy | Issue 2/2015

Login to get access

Abstract

One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and mortality in HIV-HCV coinfected individuals. Optimal treatment in this patient population is critical, as coinfection has been linked to deterioration of both disease states. The objective of this review article is to highlight the current literature on drug-drug interactions between HIV and HCV treatments. The management of the treatment of coinfection patients has been covered extensively in numerous other publications.
Literature
1.
2.
Puotia M, Rossottia R, Travia G, et al. Optimizing treatment in HIV/HCV co-infection. Dig Liver Dis. 2013;45S:S355–62.CrossRef
3.
4.
Deeks ED, Perry CM. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla RM): a review of its use in the management of HIV infection. Drugs. 2010;70(17):2315–38.PubMedCrossRef
5.
Soriano V, Vispo E, Labarga P, et al. Viral hepatitis and HIV co-infection. Antivir Res. 2010;85(1):303–15.PubMedCrossRef
6.
Weber R, Sabin CA, Friis-Miller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A: D study. Arch Intern Med. 2006;166(15):1632–41.PubMedCrossRef
7.
Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults co-infected with HIV/HCV. JAMA. 2012;308(4):370–8.PubMedCrossRef
8.
Sovaldi® (package insert). Gilead Sciences, Inc.; Foster City, CA; 2014.
9.
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.PubMedCrossRef
10.
Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomized, multicentre phase 2 trial. Lancet. 2013;381:2100–7.PubMedCrossRef
11.
Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–77.PubMedCrossRef
12.
Aptivus® (package insert). Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield, CT; 2014.
13.
14.
Kirby B, Mathias A, Rossi S, et al. No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. 63rd Annual Meeting of the American Association of the Study of Liver Diseases (AASLD) 2012. Nov 9–11, 2012, 2013; Boston, MA. (Abstract).
15.
Olysio® (package insert). Janssen Therapeutics; Titusville NJ; 2013.
16.
Izquierdo L, Helle F, François C, et al. Simeprevir for the treatment of hepatitis C virus infection. Pharmgenom Pers Med. 2014;7:241–9.
17.
Atripla® (package insert). Gilead Sciences, Inc.; Foster City, CA; 2013.
18.
Tybost® (package insert). Gilead Sciences, Inc.; Foster City, CA; 2012.
19.
Stribild® [package insert]. Gilead Sciences: Foster City, CA; August 2012.
20.
21.
Ouwerkerk-Mahadevan S, Sekar V, Simion A, et al. The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers. Presented at Infectious Disease Society Association; San Diego, CA Oct 17-21-2012 (Abstract).
22.
Harvoni® (package insert). Gilead Sciences, Inc. Foster City, CA. October 2014.
23.
Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23.PubMedCrossRef
24.
Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146(3):736–743.e1.
25.
German P, Pang PS, West S, et al. Drug interactions between direct-acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [Presentation]. Paper presented at: 15th international workshop on clinical pharmacology of HIV and hepatitis therapy; May 19–21, 2014; Washington DC.
26.
Victrelis® (package insert). MERCK & CO., Inc; Whitehouse Station, NJ; 2011.
27.
Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis. 2013;56(5):718–26.PubMedCrossRef
28.
Incivek® (package insert). Vertex Pharmaceuticals (Canada) Incorporated; Laval, Quebec; 2013.
29.
Garg V, Chandorkar G, Yang Y, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol. 2012;75:431–9.PubMedCentralCrossRef
30.
Kakuda T, Leopold L, Nijs S. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomized, two-way crossover trial. 13th international workshop on clinical pharmacology of HIV therapy, Barcelona; 2012 (Abstract).
31.
van Heeswijk R, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. 18th conference on retroviruses and opportunistic infections, Boston; 2011 (Abstract).
32.
van Heeswijk R, Garg V, Boogaerts G, Vandebosch A, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. 51th ICAAC meeting, Chicago; 2011 (Abstract).
33.
Copegus® (package insert). Genentech, Inc; South San Francisco, CA; 2013.
34.
Japour AJ, Lertora JJ, Meehan PM, et al. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:235–46.PubMedCrossRef
35.
Torriani FJ, Rodriguez-torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438–50.PubMedCrossRef
36.
Foster GR. Pegylated interferon for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs. 2010;70(2):147–65.PubMedCrossRef
37.
Viekira Pak™ (package insert). AbbVie Inc.; North Chicago, IL; 2015.
38.
Andreone P, Colombo M, Enejosa, JV, et al. PEARL-II: randomized phase 3 trial of interferon-free, 12-week regimen of ABT-450/r/ABT-267, ABT-333 with or without ribavirin in Hepatitis C virus genotype 1b-infected, treatment-experienced patients. Gastroenterology. 2104;146(5):S-159.
39.
Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594–603.PubMedCrossRef
40.
Zeuzem S, Jacobson IM, Baykal T, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604–16.PubMedCrossRef
41.
Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2104;370(21):1983–1992.
42.
Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–82.PubMedCrossRef
43.
Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015.
44.
Eron JJ, Lalezari J, Slim J, et al. Safety and efficacy of ombitasvir-450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens. J Int AIDS Soc. 2014;17(4 Suppl 3):19500.PubMedCentralPubMed
45.
Khatri A, Wang T, Wang H, et al. Drug–drug interactions of the direct-acting antiviral regimen of ABT-450/r, ombitasvir, and dasabuvir with HIV protease inhibitors. [Abstract 484] 54th interscience conference on antimicrobial agents and chemotherapy (ICAAC). Sept 5–9, 2014; Washington, DC.
46.
Khatri A, Wang T, Wang H, et al. Drug–drug interactions of the direct-acting antiviral regimen of ABT-450/r, ombitasvir, and dasabuvir with emtricitabine + tenofovir, raltegravir, rilpivirine and efavirenz. [Abstract 438] 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Sept 5–9, 2014; Washington, DC.
Metadata
Title
Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications
Authors
Kirpal Kaur
Mona A. Gandhi
Judianne Slish
Publication date
01-06-2015
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 2/2015
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-015-0061-2

Other articles of this Issue 2/2015

Infectious Diseases and Therapy 2/2015 Go to the issue

Original Research

Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates

Letter to the Editor

Reply to Farkouh RA et al. Comment on “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus Influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”

Original Research

Dengue Awareness in Latin American Populations: A Questionnaire Study

Review

Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use

Letter to the Editor

Comment on: “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”

Brief Report

Antibiotic Susceptibilities of Pseudomonas aeruginosa Isolated from Blood Samples and Antibiotic Utilization in a University Hospital in Japan
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits